(4R)-4-[(4'-bromobenzyl)oxy]-N-Boc-L-proline | 433289-50-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-4-[(4'-bromobenzyl)oxy]-N-Boc-L-proline
• 英文别名: trans-N-Boc-4-(4-bromo-benzyloxy)-L-proline；(2S,4R)-4-[(4-bromophenyl)methoxy]-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
• CAS: 433289-50-0
• 化学式: C₁₇H₂₂BrNO₅
• 分子量: 400.269
• InChiKey: QBROEULWQYSFBZ-KGLIPLIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R)-4-[(4'-bromobenzyl)oxy]-N-Boc-L-proline 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 (2S,4R)-4-[(4-bromophenyl)methoxy]pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease

  摘要：

  The N-terminal aminoacid of phenethylamide tripeptide inhibitors of the hepatitis C virus NS3 protease can be replaced with an a-hydroxy acid to obtain more 'drug like' inhibitors with low micromolar activity. The preferred S-configuration of the capping residue can be explained by molecular modeling studies. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.032
• 作为产物：
  描述：

  N-Boc-反式-4-羟基-L-脯氨酸甲酯 、 对溴溴苄 以 四氢呋喃 为溶剂， 生成 (4R)-4-[(4'-bromobenzyl)oxy]-N-Boc-L-proline
  参考文献：
  名称：

  Hydantoin compounds useful as anti-inflammatory agents

  摘要：

  具有公式(I)的化合物： 1 以及其中A是四至七成员的杂环或碳环饱和环；L和K是O或S；M是N或CH；Y是N或CH；Z是氢、烷基或取代烷基；R 1 -R 4 如说明书定义的药用可接受的盐，用于治疗炎症或免疫疾病。

  公开号：

  US20020143035A1

文献信息

• Synthesis of Zirconium Phosphonate Supported<scp>L</scp>-Proline as an Effective Organocatalyst for Direct Asymmetric Aldol Addition
  作者：Marco Angeloni、Oriana Piermatti、Ferdinando Pizzo、Luigi Vaccaro

  DOI：10.1002/ejoc.201301673

  日期：2014.3

  Stable L-proline-functionalized zirconium methyl- and/or phenylphosphonates have been prepared as amorphous solids by the precipitation of (4R)-4-[(4′-phosphonobenzyl)oxy]-L-proline and methyl- and/or phenylphosphonic acid with ZrOCl2. The supported L-proline catalysts were tested in the direct asymmetric aldol addition between several ketones and p-substituted benzaldehydes. High yields, diastereoselectivities

  通过 (4R)-4-[(4'-膦酰基苄基)氧基]-L-脯氨酸和甲基-和/或苯基膦酸的沉淀制备了稳定的 L-脯氨酸功能化的甲基和/或苯基膦酸锆与 ZrOCl2。在几种酮和对位取代的苯甲醛之间的直接不对称醛醇加成中测试了负载的 L-脯氨酸催化剂。已经实现了高产率、非对映选择性（抗/syn 高达 92:8）和对映体过量（高达 99% ee）。此外，还定义了通过简单离心有效回收催化系统的简单方案，并且在环己酮与对硝基苯甲醛的代表性羟醛加成中报告了催化剂的有效再利用。
• HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS
  申请人：Bristol-Myers Squibb Co.

  公开号：EP1339718A1

  公开（公告）日：2003-09-03
• US6710064B2
  申请人：——

  公开号：US6710064B2

  公开（公告）日：2004-03-23
• [EN] HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS<br/>[FR] COMPOSES D'HYDANTOINE UTILES EN TANT QU'AGENTS ANTI-INFLAMMATOIRES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002044181A1

  公开（公告）日：2002-06-06

  Compounds having the formula (I): [chemical drawing] and pharmaceutically-acceptable salts thereof, are useful for treating inflammatory or immune diseases, in which A is a four to seven membered heterocyclic or carbocyclic saturated ring; L and K are O or S; M is N or CH; Y is N or CH; Z is hydrogen, alkyl or substituted alkyl; and R1-R4 are as defined in the specification.
• Hydantoin compounds useful as anti-inflammatory agents
  申请人：——

  公开号：US20020143035A1

  公开（公告）日：2002-10-03

  Compounds having the formula (I): 1 and pharmaceutically-acceptable salts thereof, are useful for treating inflammatory or immune diseases, in which A is a four to seven membered heterocyclic or carbocyclic saturated ring; L and K are O or S; M is N or CH; Y is N or CH; Z is hydrogen, alkyl or substituted alkyl; and R 1 -R 4 are as defined in the specification.

  具有公式(I)的化合物： 1 以及其中A是四至七成员的杂环或碳环饱和环；L和K是O或S；M是N或CH；Y是N或CH；Z是氢、烷基或取代烷基；R 1 -R 4 如说明书定义的药用可接受的盐，用于治疗炎症或免疫疾病。